3,167 2,395
Amortization 588 580
Foreign exchange loss 102 34
Stock-based compensation 117 358
Research and product development,
net of tax credits (59) (239)
-------------------------
3,915 3,128
-------------------------
Loss before the following (1,725) (1,542)
Interest expense on convertible notes payable (165) (288)
Other net interest income 224 197
Gain on settlement of convertible
notes payable - 5,363
-------------------------
Net (loss) income and comprehensive (loss)
income for the period (1,666) 3,730
Deficit - Beginning of period (1,021) (103,671)
Restatement of capital - 98,920
-------------------------
Deficit - End of period (2,687) (1,021)
-------------------------
-------------------------
Basic (loss) earnings per common share (0.07) 0.16
-------------------------
-------------------------
Diluted (loss) earnings per common share (0.07)
'/>"/>
SOURCE Spectral Diagnostics Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany2.
US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue3.
CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy4.
Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan5.
Spectral appoints Anthony Bihl to Board of Directors6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results